|
Cutting edge: flow cytometry in myelodysplastic syndromes
|
Jul 2013
|
J Natl Compr Canc Netw
|
myelodysplastic syndromes (MDS)
|
|
Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies
|
Mar 2015
|
Curr Opin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Cyclophosphamide in severe aplastic anemia?
|
Oct 2014
|
Blood
|
aplastic anemia
|
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro
|
Jun 2020
|
Experimental Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro
|
May 2020
|
Experimental Hematology
|
myelodysplastic syndromes (MDS)
|
|
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study
|
Jun 2023
|
European Journal of Haematology
|
aplastic anemia
|
|
Cytogenetic risk stratification in myelodysplastic syndromes: are we there yet?
|
Jul 2012
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum
|
Mar 2014
|
Ann N Y Acad Sci
|
myelodysplastic syndromes (MDS)
|
|
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
|
Oct 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
